Lp (a).

IAS - TUNISIA 2nd call . Today meeting with our team in Tunisia to continue discussions and finalize the preparations prior to opening the first lipid clinic there, arranging the first ever FH symposium. #FindHoFH International Atherosclerosis Society (IAS) Samia Mora European Atherosclerosis Society fhscglobalregistry #FHWeek

IAS Inflammation Academy

Lp (a) , Premature coronary artery disease and ACS should be prioritized in lipidology and preventive cardiology service in Africa. The results of Delphi survey of EAS- LIPRA team

Wael Al-Mahmeed and IAS Research and Training Grants , Apply Now athero.org/wael-fellowshi… International Atherosclerosis Society (IAS)

A New Hope for patients with #PersistentChylomicronemia

I am so pleased after years of efforts in #FH awareness via social media platforms , TV channels , Radio stations to find Ophthalmologists in my country now ask patients to measure their LDL-c before excising lesions like that ( below) . #KnowFH #FindHoFH

Joint session between European Atherosclerosis Society and ASPC focussed on Lp(a) at #ASPC2025 in Boston, US next August

Assessment of Inflammation in Atherosclerosis IAS White paper.

#ASPC2025

Here is an opportunity for you : Join one of ASPC Working or Interest Groups .

Wael Al-Mahmeed and IAS Research Grants .

Inflammation Academy, Do not miss the opportunity to register and become a leader in the field .

IAS white paper

#ASPC2025 US, BOSTON, MA August 1-3 ASPC International Atherosclerosis Society (IAS) European Atherosclerosis Society

What factors affect #Statin use

☝️Effect of Lipid-lowering Therapies on Lp(a) Levels: A Comprehensive Meta-analysis of RCTs ☝️New evidence just published in Atherosclerosis ! 👉This comprehensive meta-analysis of 147 RCTs involving over 145,000 participants confirms that most currently available lipid-lowering

🧬 A New Era in Lipid Management? ANGPTL3 as a Game-Changer A great review by Fukami & Oike (J Atheroscler Thromb, 2025) explores the evolving therapeutic landscape targeting ANGPTL3, a key regulator of lipid metabolism. 1️⃣ ANGPTL3 inhibition lowers LDL-C and triglycerides

#ASPC2025